30 results about "Benzo Quinolizine" patented technology

The invention discloses an iridium complex and a synthesis method and application thereof. The synthesis method of the iridium complex comprises the steps that 5-chloro-8-hydroxyquinoline and a 7, 8-benzoquinoline iridium dimer are added in an organic solvent, reaction is conducted under the heating or non-heating condition, and a target compound is obtained; wherein the organic solvent is ethanol, or a composition of ethanol and one or more than two selected from water, acetone, dichloromethane, trichloromethane, dimethyl sulfoxide and N, N-dimethylformamide. It is shown by test results in the invention that the iridium complex has remarkable biological activity (the activity is obviously higher than that of cis-platinum) on cervical cancer and ovarian cancer cells, and meanwhile, the toxicity of the iridium complex on normal hepatocytes of human body is extremely low (IC50 is higher than 80<mu>M).

The present invention relates to new solid forms of the compound (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below.

The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease.

The invention discloses an 8-hydroxyquinoline derivative iridium (III) complex as well as a preparation method and application thereof, and belongs to the field of medicines. The chemical name of the compound is 2-methylpyridino[3,2-a]-pyridino[1',2':1,2]imidazo[4,5-c]phenazine.bisbenzoquinolinyl iridium(III) hexafluorophosphate . The preparation method comprises the following steps: reacting 8-hydroxyquinoline with hydrochloric acid and NaClO3; adding anhydrous potassium carbonate; adding 2-amino-5-methylpyridine; adding o-phenylenediamine; obtaining a compound 3a; reacting 7,8-benzoquinoline with iridium trichloride hydrate to obtain a compound 4; and reacting the compound 3a with a compound 4 to obtain the 8-hydroxyquinoline derivative iridium (III) complex. The in-vitro anti-tumor activity of the compound on a human ovarian cancer drug-resistant strain SK-OV-3/DDP is greater than that of an 8-hydroxyquinoline derivative ligand and a metal-based anti-cancer drug cis-platinum; and the toxicity to normal cells HL-7702 is very low, and a good effect of targeted inhibition of human ovarian cancer proliferation is reflected.

The present invention relates to a process for manufacturing (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]guinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below and pharmaceutically acceptable salts thereof

The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease.

The invention also relates to a new intermediate of said process.

The invention provides a nitrogen-containing ligand iridium complex as well as a preparation method and application thereof, and belongs to the technical field of synthesis and application of inorganic materials. According to the iridium complex, firstly, a benzoquinoline iridium dimeric intermediate is synthesized from iridium trichloride and benzoquinoline, 4, 4'-dimethyl-2, 2'-bipyridyl is oxidized into bipyridine formaldehyde by using selenium dioxide at the same time, then hydroxylamine hydrochloride is added to reduce the bipyridine formaldehyde into bipyridine formaldehyde oxime, bipyridine formaldehyde oxime is used as a third ligand and reacts with the benzoquinoline iridium dimer to obtain a nitrogen-containing ligand iridium complex with a novel structure, and the nitrogen-containing ligand iridium complex can be used as a fluorescent probe for rapid identification and even trace detection of hypochlorite ions. The complex is simple in synthesis process, mild in reaction condition, small in reagent dosage, low in manufacturing cost, small in environmental pollution and good in optical property and biocompatibility. A hypochlorite ion fluorescent probe constructed by using the complex is high in sensitivity, good in selectivity, good in anti-interference performance, wide in concentration detection range and low in detection limit.

The invention discloses a method for synthesizing 1-arylbenzo[f]quinoline derivatives, which belongs to the technical field of chemical synthesis. The method is to use aromatic aldehyde, 2-naphthylamine and McFarlandic acid as raw materials, polyethylene glycol PEG400 as solvent and catalyst, reflux reaction at 80~100°C for 14~20h, suction filtration, washing with water, and the obtained crude product is passed through The target product was obtained by recrystallization from absolute ethanol. The present invention synthesizes a series of 1-arylbenzo[f]quinoline derivatives through three-component one-pot reaction, which has the advantages of mild reaction conditions, simple synthesis process, high yield and low cost; environment-friendly, non-toxic , post-processing is simple and safe, and meets the requirements of green chemistry.

The invention relates to a heteroaryl compound according to formula (I) and to the use thereof in electronic devices.

The invention discloses a mixed quinoline derivative iridium (III) complex as well as a preparation method and application thereof, and belongs to the field of medicines. The chemical name of the compound is hexafluorophosphorylate.pyrido [3, 2-a] pyrido [1 ', 2': 1, 2] imidazo [4, 5-c] phenazine. Dibenzoquinoline iridium (III). The preparation method comprises the following steps: reacting 8hydroxyquinoline with hydrochloric acid and NaClO3; adding anhydrous potassium carbonate; adding 2-aminopyridine; adding o-phenylenediamine; obtaining a compound 3a; reacting 7,8-benzoquinoline with iridium trichloride hydrate to obtain a compound 4; and reacting the compound 3a with the compound 4 to obtain the mixed quinoline derivative iridium (III) complex. The in-vitro anti-tumor activity of the compound on a human ovarian cancer drug-resistant strain SK-OV-3/DDP is greater than that of an 8-hydroxyquinoline derivative ligand and a metal-based anti-cancer drug cis-platinum; the toxicity to normal cells HL-7702 is very low, and a good effect of targeted inhibition of human ovarian cancer proliferation is reflected.

The invention discloses a human ovarian cancer cell inhibitor as well as a preparation method and application thereof, and belongs to the field of medicines. The chemical name of the compound is hexafluorophosphorylate.2,12,13-trimethylpyrido[3, 2-a]pyrido[1',2':1,2]imidazo[4, 5-c]phenazine.bis-benzoquinolineiridium (III). The preparation method comprises the following steps: reacting 8-hydroxyquinoline with hydrochloric acid and NaClO3; adding anhydrous potassium carbonate; adding 2-amino-5-methyl pyridine; adding 4,5-dimethyl o-phenylenediamine to prepare a compound (3a); reacting 7,8-benzoquinoline with iridium trichloride hydrate to obtain a compound 4; and reacting the compound 3a with a compound 4 to obtain the human ovarian cancer cell inhibitor. The in-vitro anti-tumor activity of the compound on a human ovarian cancer drug-resistant strain SK-OV-3/DDP is greater than that of an 8hydroxyquinoline derivative ligand and a metal-based anti-cancer drug cis-platinum; the toxicity to normal cells HL-7702 is very low, and a good effect of targeted inhibition of human ovarian cancer proliferation is reflected.

The present invention relates to a new process for manufacturing (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-g]quinoline with formula (Ib) below, (4aR,10aR)-1-Propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol with formula (I) below and salts thereof.

Both compounds are for use in the treatment of neurodegenerative diseases and disorders such as Parkinson's Disease. The invention also relates to new intermediate compounds of said process.

The instant invention relates to novel prodrugs of optically pure benzoquinolizine-2-carboxylic acid and pharmaceutical compositions that include the prodrugs. In particular, the present invention relates to the sulfonic acid salts of L-alanine and L-valine prodrugs of S-(−)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid. The compounds and compositions of the invention can be used to treat bacterial Gram-positive, Gram-negative and anaerobic infections, especially infections caused by resistant Gram-positive organism and Gram-negative organism, mycobacterial infections and emerging nosocomial pathogen infections.